Pharmaniaga Berhad Past Earnings Performance

Past criteria checks 0/6

Pharmaniaga Berhad's earnings have been declining at an average annual rate of -32.4%, while the Healthcare industry saw earnings growing at 22.4% annually. Revenues have been growing at an average rate of 6% per year.

Key information

-32.4%

Earnings growth rate

-32.0%

EPS growth rate

Healthcare Industry Growth31.5%
Revenue growth rate6.0%
Return on equityn/a
Net Margin-1.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Jul 18
Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

May 09
Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Apr 19
Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Oct 03
Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Jul 19
Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Feb 18
Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Dec 10
Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Nov 24
Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Aug 27
We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

May 28
Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

Revenue & Expenses Breakdown

How Pharmaniaga Berhad makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KLSE:PHARMA Revenue, expenses and earnings (MYR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 243,479-562850
31 Mar 243,489-572970
31 Dec 233,404-803020
30 Sep 233,507-6673770
30 Jun 233,487-6543000
31 Mar 233,399-6552950
31 Dec 223,481-6302930
30 Sep 223,3301002240
30 Jun 224,5681643260
31 Mar 224,9841773220
31 Dec 214,8151723060
30 Sep 214,738803410
30 Jun 213,230322190
31 Mar 212,699282050
31 Dec 202,725272090
30 Sep 202,806-1452230
30 Jun 202,898-1462310
31 Mar 202,854-1462290
31 Dec 192,821-1492300
30 Sep 192,701342110
30 Jun 192,572481970
31 Mar 192,553442080
31 Dec 182,385422050
30 Sep 182,402602180
30 Jun 182,388482330
31 Mar 182,324522220
31 Dec 172,324542270
30 Sep 172,294312280
30 Jun 172,234412310
31 Mar 172,248462350
31 Dec 162,189462240
30 Sep 162,286622290
30 Jun 162,296692140
31 Mar 162,277712140
31 Dec 152,189842120
30 Sep 152,1361052030
30 Jun 152,1141002090
31 Mar 152,126992050
31 Dec 142,123941970
30 Sep 142,064781860
30 Jun 142,002671760
31 Mar 141,915571720
31 Dec 131,947551800

Quality Earnings: PHARMA is currently unprofitable.

Growing Profit Margin: PHARMA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PHARMA is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.

Accelerating Growth: Unable to compare PHARMA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PHARMA is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-0.3%).


Return on Equity

High ROE: PHARMA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies